200 related articles for article (PubMed ID: 26381660)
1. Angiogenesis Markers in Gynecological Tumors and Patents for Anti-Angiogenic Approach: Review.
Abdalla DR; Simoens C; Bogers JP; Murta EF; Michelin MA
Recent Pat Anticancer Drug Discov; 2015; 10(3):298-307. PubMed ID: 26381660
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis: prognostic and therapeutic implications in gynecologic and breast malignancies.
Sauer G; Deissler H
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):45-9. PubMed ID: 12544501
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets.
Rasila KK; Burger RA; Smith H; Lee FC; Verschraegen C
Int J Gynecol Cancer; 2005; 15(5):710-26. PubMed ID: 16174217
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
[TBL] [Abstract][Full Text] [Related]
5. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
Thanapprapasr D; Hu W; Sood AK; Coleman RL
Curr Pharm Des; 2012; 18(19):2713-9. PubMed ID: 22390757
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in malignancies of the female genital tract.
Abulafia O; Triest WE; Sherer DM
Gynecol Oncol; 1999 Feb; 72(2):220-31. PubMed ID: 10021305
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.
Wei XW; Zhang ZR; Wei YQ
Expert Opin Investig Drugs; 2013 Sep; 22(9):1181-92. PubMed ID: 23782133
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic strategies, compounds, and early clinical results in breast cancer.
Morabito A; Sarmiento R; Bonginelli P; Gasparini G
Crit Rev Oncol Hematol; 2004 Feb; 49(2):91-107. PubMed ID: 15012971
[TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis in gynecologic cancers.
Zand B; Coleman RL; Sood AK
Hematol Oncol Clin North Am; 2012 Jun; 26(3):543-63, viii. PubMed ID: 22520979
[TBL] [Abstract][Full Text] [Related]
12. Strategies for suppressing angiogenesis in gynecological cancers.
Ma WW; Jimeno A
Drugs Today (Barc); 2007 Apr; 43(4):259-73. PubMed ID: 17460787
[TBL] [Abstract][Full Text] [Related]
13. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
14. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels.
Fonsatti E; Altomonte M; Nicotra MR; Natali PG; Maio M
Oncogene; 2003 Sep; 22(42):6557-63. PubMed ID: 14528280
[TBL] [Abstract][Full Text] [Related]
15. The merits of vascular targeting for gynecologic malignancies.
Kamat AA; Sood AK
Curr Oncol Rep; 2005 Nov; 7(6):444-50. PubMed ID: 16221381
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?
Memtsas V; Zarros A; Theocharis S
Expert Opin Ther Targets; 2009 Sep; 13(9):1105-20. PubMed ID: 19604124
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis and breast cancer].
Bachelot T; Ray-Coquard I; Cassier P; Blay JY
Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
[TBL] [Abstract][Full Text] [Related]
18. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers.
Schmid BC; Oehler MK
Curr Treat Options Oncol; 2015 Jan; 16(1):318. PubMed ID: 25750175
[TBL] [Abstract][Full Text] [Related]
19. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
